Online inquiry

IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5507MR)

This product GTTS-WQ5507MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17A&IL17F gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002190.3; NM_052872.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 112744
UniProt ID Q16552; Q96PD4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5507MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3170MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ7384MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ14877MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ1345MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-806
GTTS-WQ8349MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA hPAM4
GTTS-WQ13473MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ10116MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LAG-525
GTTS-WQ9320MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMP-321
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW